目的 探讨注射用二丁酰环磷腺苷钙联合左西孟旦注射液治疗慢性心力衰竭的临床疗效。方法 选取2016年5月—2017年5月在洛阳市第三人民医院进行治疗的慢性心力衰竭患者92例作为研究对象，根据随机数字表将患者分为对照组和治疗组，每组各46例。对照组静脉滴注左西孟旦注射液，10 mL加入到5%葡萄糖注射液500 mL中，1次/d。治疗组在对照组基础上静脉滴注注射用二丁酰环磷腺苷钙，40 mg加入到5%葡萄糖注射液250 mL中，1次/d。两组患者均连续治疗14 d。观察两组的临床疗效，比较两组的心功能指标、血清细胞因子和6 min步行试验（6 WMT）。结果 治疗后，对照组和治疗组的总有效率分别为80.43%、95.65%，两组比较差异有统计学意义（P<0.05）。治疗后，两组左心室射血分数（LVEF）、每分钟排血量（CO）明显升高，左心室舒张末期内径（LVEDD）、左心室收缩末期容积（LVESV）、左心室收缩末期内径（LVESD）明显下降，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组心功能指标明显优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清β内啡肽（β-EP）、氨末端脑利钠肽前体（NT-proBNP）、肌钙蛋白T（cTnT）水平显著降低，类胰岛素生长因子1（IGF-1）、心肌营养素1（CT-1）水平显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组血清细胞因子明显优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组6 WMT距离均显著增加，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组6 WMT距离明显长于对照组，两组比较差异具有统计学意义（P<0.05）。结论 注射用二丁酰环磷腺苷钙联合左西孟旦注射液治疗慢性心力衰竭具有较好的临床疗效，可改善患者心功能，调节血清NT-proBNP、β-EP、cTnT、IGF-1、CT-1水平，提高患者运动耐量，具有一定的临床推广应用价值。

Objective To explore the clinical efficacy of Calcii Dibutyry-ladenosini Cyclophosphas for injection combined with Levosimendan Injection in treatment of chronic heart failure. Methods Patients (92 cases) with chronic heart failure in Luoyang Third People's Hospital from May 2016 to May 2017 were randomly divided into control and treatment groups, and each group had 46 cases. Patients in the control group were iv administered with Levosimendan Injection, 10 mg added into 5% glucose solution 500 mL, once daily. Patients in the treatment group were iv administered with Calcii Dibutyry-ladenosini Cyclophosphas for injection on the basis of the control group, 40 mg added into 5% glucose solution 250 mL, once daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and cardiac function indexes, serum cytokines, 6 WMT in two group were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.43% and 95.65%, respectively, and there was difference between two groups (P < 0.05). After treatment, LVEF and CO in two groups were significantly increased, but LVEDD, LVESV, and LVESD in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And cardiac function indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P< 0.05). After treatment, β-EP, NT-proBNP, and cTnT levels in two groups were significantly decreased, but IGF-1 and CT-1 levels in two groups were significantly increased, and the difference was statistically significant in the same group (P <0.05). And serum cytokines in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the distance of 6 WMT in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the distance of 6 WMT in the treatment group was significantly longer than that in the control group, with significant difference between two groups (P < 0.05). Conclusion Calcii Dibutyry-ladenosini Cyclophosphas for injection combined with Levosimendan Injection has clinical curative effect in treatment of chronic heart failure, can improve the cardiac function of patients, regulate the levels of NT-proBNP, β-EP, IGF-1, and CT-1, and improve the exercise tolerance of patients, which has a certain clinical application value.